AstraZeneca slashes 12% of its workforce - Merck's diabetes franchise may help it offset loss of Singular - Sucampo/Takeda's constipation treatment Amitiza meets primary endpoint in Phase III study of opioid-induced bowel dysfunction study - FDA objects to Abraxane white paper distributed at ASCO meeting
